The CCR Sequencing Facility Provides Cutting-Edge NGS Service to NCI Community

Authors

• LR Wilson
• NW Plummer
• IY Evsyukova
• K Konrad
• D Patino
• CL Stewart
• KG Smith
• SA Fry
• AL Deal
• S Panda
• VW Kilonzo
• NR Sciolino
• JD Cushman
• P Jensen

Abstract

The Center for Cancer Research Sequencing Facility (CCR-SF) is committed to utilizing high-throughput sequencing technologies across different Next Generation Sequencing (NGS) platforms and applications. At CCR-SF, we apply the highest quality standards to all projects and communicate project status on a regular basis. We also work closely with each investigator from experimental design through data analysis to ensure that the sequencing experiment delivers high-quality data. Recently, we have seen many new sequencing technologies and applications enter the market. At CCR-SF, we are actively testing the newest sequencing technologies and applications available, to ensure that the NCI community can remain at the leading edge of next-generation sequencing technologies.

Here we introduce the new applications and sequencing platforms that were launched at CCR-SF recently, which include PIP-Seq Single-Cell RNA-Seq from Fluent Biosciences, Mission Bio Tapestri single-cell multi-omics (DNA+Protein), PacBio MAS-seq, targeted RNA Iso-seq, and whole genome 5-mC and 5-hmC detection and analysis. We also acquired several new instruments, which include the Chromium X high-throughput single cell RNA-seq platform from 10X Genomics, the Illumina short read sequencer NovaSeq X Plus, the PacBio Revio and Oxford Nanopore P24 PromethION long read sequencing systems, as well as the Xdrop Sort for targeted DNA sequencing from Samplix.

Scientific Focus Area: Research Support Services

This page was last updated on Monday, September 25, 2023